HIMSS: The evolving landscape of innovations for more equitable obesity care

GLP-1 medications have become wildly popular for weight loss and show favorable clinical results in multiple other conditions. These pioneering drugs can potentially improve the lives of many. However, the current high-cost and supply constraints raise ethical questions on who can and cannot afford them and who can and cannot access them.

The success of and access to GLP1’s may lead to the acceleration of new care models and product categories, as well as changing business models and product redesign. Ipsos’ Jackie Ilacqua joins a HIMSS panel discussion on the foresight to equitable obesity care and what's required within health system management to adapt successfully.

During this session, you will:

• Understand the disease burden in countries facing an obesity epidemic and the potential of GLP-1 development to radically improve health outcomes
• Discover GLP-1 usage trends, patient outcomes, and how today’s affordability, access, and scarcity is consequential for tomorrow
• Learn how innovations, such as telehealth, is making access to weight loss treatment accessible
• Discuss the landscape for health systems on changing patient loads and what medical device and digital health companies might need to be thinking about now to adapt 
• Walk away with resources to help your organization to be informed of the anticipated market shifts

To join us, please click here.

Be sure to also access this month's deep exploration of GLP-1s impact on a wide range of industries, Reshaping Society: Insights to Activate.